What is the price of nvcn stock?
One share of NVCN stock can currently be purchased for approximately $0.45. How much money does Neovasc make? Neovasc has a market capitalization of $30.42 million and generates $1.96 million in revenue each year. The medical equipment provider earns $-28.69 million in net income (profit) each year or ($0.46) on an earnings per share basis.
Is Neovasc Inc (nvcn) a publicly traded stock?
Neovasc Inc. is currently listed on NASDAQ under NVCN. One share of NVCN stock can currently be purchased for approximately $ 0.76. Is Neovasc Inc. a publicly traded stock? Yes, Neovasc Inc. is publicly traded and listed as NVCN on the NASDAQ. It is currently being traded for approximately $ 0.76. View more information on NVCN here.
Is Neovasc (nvcn) poised to beat earnings estimates?
Neovasc (NVCN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. Neovasc (NVCN) delivered earnings and revenue surprises of 66.67% and -6.55%, respectively, for the quarter ended December 2020.
What does nvcn stand for?
Vancouver, British Columbia--(Newsfile Corp. - October 15, 2019) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina,...
Is NVCN stock a buy?
Is NEOVASC Stock a good buy in 2022, according to Wall Street analysts? The consensus among 1 Wall Street analyst covering (NASDAQ: NVCN) stock is to Strong Buy NVCN stock.
Did NVCN reverse split?
The first split for NVCN took place on September 21, 2018. This was a 1 for 100 reverse split, meaning for each 100 shares of NVCN owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 10 share position following the split.
Will neovasc recover?
If you are looking for stocks with good return, Neovasc Inc can be a profitable investment option. Neovasc Inc quote is equal to 5.970 USD at 2022-06-02. Based on our forecasts, a long-term increase is expected, the "NVCN" stock price prognosis for 2027-05-26 is 6.239 USD.
Is neovasc a good buy?
Neovasc has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Should I buy or sell Neovasc stock right now?
1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Neovasc in the last twelve months. There are currently 1 buy rati...
What is Neovasc's stock price forecast for 2022?
1 analysts have issued 1 year price objectives for Neovasc's shares. Their forecasts range from $125.00 to $125.00. On average, they predict Neovas...
How has Neovasc's stock performed in 2022?
Neovasc's stock was trading at $11.7150 at the start of the year. Since then, NVCN shares have decreased by 53.5% and is now trading at $5.45. Vie...
When is Neovasc's next earnings date?
Neovasc is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022. View our earnings forecast for Neovasc .
How were Neovasc's earnings last quarter?
Neovasc Inc. (NASDAQ:NVCN) released its quarterly earnings data on Tuesday, November, 9th. The medical equipment provider reported ($2.75) EPS for...
When did Neovasc's stock split? How did Neovasc's stock split work?
Shares of Neovasc reverse split on the morning of Friday, April 29th 2022. The 1-25 reverse split was announced on Friday, April 29th 2022. The num...
Who are Neovasc's key executives?
Neovasc's management team includes the following people: Mr. Fredericus A. Colen , Pres, CEO & Director (Age 70, Pay $2.59M) Mr. Christopher Cla...
Who are some of Neovasc's key competitors?
Some companies that are related to Neovasc include Pro-Dex (PDEX) , Titan Medical (TMDI) , Biostage (BSTG) , Daxor (DXR) , Modular Medical (MO...
What other stocks do shareholders of Neovasc own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Neovasc investors own include Biopharmx (BPMX) , Allstate...
Neovasc (NVCN) Reports Q3 Loss, Lags Revenue Estimates
Neovasc (NVCN) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Neovasc (NVCN) delivered earnings and revenue surprises of -22.22% and -41.42%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Neovasc Receives FDA Approval for COSIRA-II Clinical Trial
Neovasc (NVCN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What is the NVCN?
The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Neovasc Inc. (NASDAQ: NVCN) is a medical device company focused on developing, manufacturing, and marketing products for the cardiovascular market.
What is NVCN in medical?
Neovasc Inc (NASDAQ: NVCN) has announced the publication of an article highlighting the long-term outcomes of patients suffering from refractory angina treated with the Neovasc Reducer system in the International Journal of Cardiology. The study dubbed RESOURCE is an observational, retrospective registry that includes 658 patients in Europe, the U.K., and Israel. The prespecified endpoints of the trial were the amelioration of anginal symptoms, evaluated with chest pain severity score and the ra
Signals & Forecast
Neovasc Inc (NASDAQ: NVCN) has announced the publication of an article highlighting the long-term outcomes of patients suffering from refractory angina treated with the Neovasc Reducer system in the International Journal of Cardiology.
Support, Risk & Stop-loss
There are mixed signals in the stock today. The Neovasc Inc. stock holds a buy signal from the short-term moving average; at the same time, however, the long-term average holds a general sell signal. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock.
Is Neovasc Inc. stock A Buy?
Neovasc Inc. finds support from accumulated volume at $0.46 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
About Neovasc Inc
Neovasc Inc. holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.
Golden Star Signal
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets cardiovascular products worldwide. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina.
Top Fintech Company
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.
What is a neovasc?
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
Where is Neovasc located?
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets medical devices for cardiovascular marketplace in Europe, Canada, the United States, and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment ...
